Vertex Reports Second Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Vertex Pharma (VRTX) Tops Q2 EPS by 25c, Beats on Revenue; Offers FY25 Revenue Guidance
August 4, 2025 4:03 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $4.52, $0.25 better than the analyst estimate of $4.27. Revenue for the quarter came in at $2.96 billion versus the consensus estimate of $2.91 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.85-12 billion, versus the consensus of... More
